One of the hallmarks of the NMO-IgG seropositive testing in humans with NMO disease is the prognostic implication of more frequent recurrences and worse neurologic outcome with increased disability compared to individuals with NMO whose serum does not react with AQP4 [8]. The gene discussed is AQP4; the disease is neuromyelitis optica.